Clinical Trials

486 enrolled

CNS

Glioblastoma

NCT04031677 2026-03-18

STRASS2

250 enrolled

Sarcoma

Leiomyosarcoma, Liposarcoma

NCT05100862 2026-03-18

MAHOGANY

780 enrolled

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05256225 2026-03-18

Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

360 enrolled

Neoplasms, Endometrial Neoplasms

NCT05281471 2026-03-18

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

186 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Vaccinia

NCT05941741 2026-03-18

IC Plus Low-dose Radiation Plus Cadonilimab in LANPC

380 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT06058377 2026-03-18

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

3,680 enrolled

Anatomic Stage II Breast Cancer AJCC v8

NCT06151574 2026-03-18

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

416 enrolled

Lung Neoplasms

NCT06337318 2026-03-18

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

600 enrolled

Classic Follicular Lymphoma

NCT06377852 2026-03-18

The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

Breast Neoplasms

NCT06422806 2026-03-18

Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas

365 enrolled

Sarcoma

Liposarcoma, Histiocytoma, Malignant Fibrous

NCT06496178 2026-03-18

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT06498635 2026-03-18

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

306 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06510374 2026-03-18

ABLE-32

454 enrolled

Intermediate Risk Non-Muscle Invasive Bladder Cancer

NCT06524544 2026-03-18

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

320 enrolled

Carcinoma, Transitional Cell

NCT06549595 2026-03-18

A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

1,018 enrolled

Lymphoma, Follicular

NCT06568172 2026-03-18

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

DermatologicHead & NeckSarcoma

420 enrolled

Eyelid Squamous Cell Carcinoma

NCT06589804 2026-03-18

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment

158 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms

NCT06931717 2026-03-18

ARCH

390 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06970847 2026-03-18

AMPLIFY

220 enrolled

Prostatic Neoplasms

NCT06973187 2026-03-18

A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06980480 2026-03-18

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

183 enrolled

Plasma cell

Multiple Myeloma

NCT07061977 2026-03-18

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

336 enrolled

Locally Advanced Cervical Adenocarcinoma

NCT07195695 2026-03-18

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

400 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07205822 2026-03-18

TB06

100 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07277231 2026-03-18

A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia

Leukemia, Lymphocytic, Chronic, B-Cell

NCT02064673 2026-03-17

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

608 enrolled

Prostatic Neoplasms

NCT04267848 2026-03-17

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

1,210 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04269902 2026-03-17

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05738694 2026-03-17

Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma

298 enrolled

Carcinoma, Renal Cell

NCT06072781 2026-03-17

RAMP 301

270 enrolled

Low Grade Serous Ovarian Cancer

NCT06615479 2026-03-17

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

440 enrolled

Plasma cell

Multiple Myeloma, Recurrence

NCT06950385 2026-03-17

SERENTA

168 enrolled

Adenomatous Polyposis Coli, Polyps

NCT07221253 2026-03-17

AB02

1,100 enrolled

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence

NCT07396480 2026-03-17

Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial

186 enrolled

Other neoplasm

Venentoclax

NCT03486873 2026-03-16

MK-3475-587

Other hematologic neoplasm

3,500 enrolled

Hematologic Neoplasms

NCT04628026 2026-03-16

Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

Other hematologic neoplasm

650 enrolled

Leukemia, Myeloid, Acute

NCT04928846 2026-03-16

A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

698 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05253651 2026-03-16

MOUNTAINEER-03

400 enrolled

Colorectal Neoplasms

NCT05438043 2026-03-16

A Study of Daratumumab

Plasma cell

Multiple Myeloma

NCT06056830 2026-03-16

CLARIFY

383 enrolled

Prostatic Neoplasms

NCT06136559 2026-03-16

BELLWAVE-011

1,200 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06284317 2026-03-16

ADOPT-lung

290 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06345729 2026-03-16

KANDLELIT-004

600 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT06357533 2026-03-16

TROPION-Lung10

675 enrolled

Carcinoma, Non-Small-Cell Lung

NCT06561048 2026-03-16

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

150 enrolled

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

NCT06607627 2026-03-16

PK, PD, Safety, and Efficacy Study of Gefurulimab in Pediatric Patients With AChR+ Generalized Myasthenia Gravis

12 enrolled

Myasthenia Gravis

NCT06731478 2026-03-16

Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer

726 enrolled

Stomach Neoplasms

NCT06767527 2026-03-16

AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer

416 enrolled